| payload |
{"created_at":"2026-04-08T21:48:34.365 {"created_at":"2026-04-08T21:48:34.365482+00:00","dedupe_key":"signal_enriched:news_delta:15ddc98211ad5a1e","evidence_event_ids":["evt_fa1be9f48e71"],"signal_type":"news_headline_delta","source":"news_rss","value":{"aggregator_url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ1ktNDdSNFRYcEtFWXJveWRvXzdqb1BZYlMwZllZZ2FaRFY5MUk2Q2xMOWx6QUNEdTR1LVNqWXRnVzlkbTM0VTFMejJpd1RaM0dIbjNMY2syMnF4NWJBUHY1SjhpODBORmFYNG1PLUNTWlJvMDNRRTlaVTZyTm16Rk9LOVhkT2UtZ0pYc2JCaGhGdGpKSUQtUw?oc=5","as_of":"2026-04-08T21:48:34.365482+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ1ktNDdSNFRYcEtFWXJveWRvXzdqb1BZYlMwZllZZ2FaRFY5MUk2Q2xMOWx6QUNEdTR1LVNqWXRnVzlkbTM0VTFMejJpd1RaM0dIbjNMY2syMnF4NWJBUHY1SjhpODBORmFYNG1PLUNTWlJvMDNRRTlaVTZyTm16Rk9LOVhkT2UtZ0pYc2JCaGhGdGpKSUQtUw?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_f90014c738c9c1fc","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-09T22:13:36.181676+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ1ktNDdSNFRYcEtFWXJveWRvXzdqb1BZYlMwZllZZ2FaRFY5MUk2Q2xMOWx6QUNEdTR1LVNqWXRnVzlkbTM0VTFMejJpd1RaM0dIbjNMY2syMnF4NWJBUHY1SjhpODBORmFYNG1PLUNTWlJvMDNRRTlaVTZyTm16Rk9LOVhkT2UtZ0pYc2JCaGhGdGpKSUQtUw?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"washingtonpost.com","publisher_resolution":"payload_source_domain","requested_url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ1ktNDdSNFRYcEtFWXJveWRvXzdqb1BZYlMwZllZZ2FaRFY5MUk2Q2xMOWx6QUNEdTR1LVNqWXRnVzlkbTM0VTFMejJpd1RaM0dIbjNMY2syMnF4NWJBUHY1SjhpODBORmFYNG1PLUNTWlJvMDNRRTlaVTZyTm16Rk9LOVhkT2UtZ0pYc2JCaGhGdGpKSUQtUw?oc=5","source_event_id":"evt_fa1be9f48e71","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"426f549f6ae15112","published_at":"2026-04-08T21:25:12+00:00","publisher_domain":"washingtonpost.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.62,"dates_mentioned":[],"entities":[{"asset_class":"healthcare","name":"GLP-1 drugs (GLP-1 receptor agonists)","relevance":"high","symbol":"","type":"drug_class"},{"asset_class":"biotech","name":"GLP-1 receptor","relevance":"high","symbol":"","type":"biological_target"},{"asset_class":"media","name":"The Washington Post","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"media","name":"BBC","relevance":"low","symbol":"","type":"publisher"},{"asset_class":"media","name":"The Guardian","relevance":"low","symbol":"","type":"publisher"},{"asset_class":"media","name":"Scientific American","relevance":"low","symbol":"","type":"publisher"},{"asset_class":"media","name":"Nature","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"research","information_gaps":["No specific genes, study names, effect sizes, or which GLP-1 drugs (e.g., semaglutide, liraglutide, tirzepatide) are explicitly identified in the provided text.","The direction/magnitude of benefit for different genetic groups is not provided in the supplied content.","No near-term clinical or regulatory actions (e.g., guideline changes, trial starts) are specified\u2014only research/interpretation is implied.","The cleaned article text appears to contain only page styling/HTML artifacts, so detailed article-specific claims cannot be verified from the provided 'Article Text'."],"key_facts":["The Washington Post headline states that if a person is not losing weight with GLP-1 drugs, genetics may be one reason.","The provided source summary indicates genetic predictors of GLP-1 receptor agonist weight loss and side effects are discussed.","The provided source summary indicates scientists suggest genetics may help explain variability in results from weight-loss drugs (GLP-1).","The provided source summary indicates coverage that how well GLP-1 weight loss drugs work may depend on genetics."],"numeric_claims":[],"primary_claim":"Genetic predictors of GLP-1 receptor agonist response may be one reason some patients do not lose weight with GLP-1 drugs.","relevance_score":0.42,"sentiment":"neutral","source_quality":"high","summary":"The Washington Post highlights that genetic factors may explain why some people do not lose weight as expected on GLP-1 receptor agonist drugs. The broader coverage suggests genetic predictors could help identify who benefits most and who experiences different side-effect or weight-loss responses.","topics":["pharmacogenomics","genetics","weight loss","GLP-1 receptor agonists","personalized medicine","clinical response variability"]},"source":"The Washington Post","source_domain":"washingtonpost.com","source_url":"https://www.washingtonpost.com","summary":"If you aren\u2019t losing weight with GLP-1 drugs, this may be one reason why The Washington Post Genetic predictors of GLP1 receptor agonist weight loss and side effects Nature New light shed on who benefits most from weight-loss jabs BBC Genetics may help explain why results from weight-loss jabs vary, say scientists The Guardian How well GLP-1 weight loss drugs work may depend on your genetics Scientific American","title":"If you aren\u2019t losing weight with GLP-1 drugs, this may be one reason why - The Washington Post","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}}... |